Product concentration
Nearly all revenue comes from one therapy platform, so any slowdown in adoption or product issues would affect results materially.
- Scope
- Sales of Inspire system accounted for substantially all revenue
- Materiality
- high
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea. Its proprietary Inspire system senses breathing and delivers mild hypoglossal nerve stimulation to keep the airway open, and it is sold primarily to hospitals and ambulatory surgery centers in the U.S. with additional international distribution.
7,1 %
85,4 %
15,9 %
+13,6 %
6.08
4.56
| % | |
|---|---|
| Inspire therapy systems | 95% Implantable neurostimulation systems used to treat moderate to severe OSA. |
| Next-generation Inspire V | 3% The newer platform launched in the U.S. to expand adoption and upgrade the installed base. |
| International distribution sales | 2% Sales through distributors in selected Asia-Pacific markets and other non-U.S. countries. |
The company sells to hospitals and ambulatory surgery centers, which are the purchasing entities for the procedure,...
Primary purchasing customers that acquire the Inspire system for implantation procedures and need reimbursement support.
Clinical referral and procedure-driving users who identify eligible OSA patients and influence adoption.
Patients covered by insurers and Medicare who need positive coverage policies for treatment access.
Channel partners in Japan, Singapore, Hong Kong, Thailand, and other select markets that sell and promote the therapy locally.
Government healthcare channel that purchases under contract for eligible patients.
Revenue is heavily concentrated in the United States, which represented 95.6% of 2025 revenue, while all other...
The company is focused on expanding adoption of Inspire therapy through physician education, direct-to-consumer...
A newer platform can refresh demand, support upgrades, and improve the product's competitive position.
Coverage policies are essential because treatment uptake depends on payor approval and patient affordability.
The business relies on referral-driven adoption and patient activation for procedure growth.
Non-U.S. markets are still small but offer long runway if approvals and reimbursement improve.
The company is highly dependent on a single product franchise, so adoption, reimbursement, and competitive pressure...
Nearly all revenue comes from one therapy platform, so any slowdown in adoption or product issues would affect results materially.
The therapy depends on third-party payor approval, prior authorization, and coverage policy maintenance.
Core functions such as manufacturing, distribution, and patient data handling rely on IT systems and third parties.
Alternative OSA treatments, including GLP-1 drugs and competing neurostimulation devices, may divert patients or physicians.
Growth depends on a large direct sales organization and enough trained surgeons to perform procedures.
Non-U.S. expansion requires approvals, local compliance, and exposure to currency and trade issues.
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
NSPR · Surgical & Medical Instruments & Apparatus
ISPR · Cigarettes
ISRG · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Intuitive Surgical designs and sells robotic-assisted surgical systems and related instruments, accessories, software, and services used to perform minimally invasive procedures.
GMED · Surgical & Medical Instruments & Apparatus
Globus Medical is a U.S.-based medical device company focused on musculoskeletal care, with products used in spine, orthopedic trauma, hip, knee, extremity and neurosurgical procedures.
RMSL · Services-Personal Services
: 28/04/2026